IgG4-related disease: advances in pathophysiology and treatment.
IgG4
IgG4-related disease
fibrosis
glucocorticoids
rituximab
treatment
Journal
Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
26
4
2023
pubmed:
25
3
2023
entrez:
24
3
2023
Statut:
ppublish
Résumé
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disease affecting multiple organs. In recent years basic and translational research has unveiled the role of different cellular subtypes and cytokines in inducing and perpetuating the pathological process, eventually leading to fibrosis of affected tissues. Hopefully, the growing knowledge of the disease pathogenesis will lead to patient-tailored treatments in the near future. This review focuses on the most recent discoveries concerning the pathogenic mechanisms underlying IgG4-RD and highlights their potential role as specific therapeutic targets. IgG4-RD is a systemic and multifaceted disease. Its sensitivity to glucocorticoids is well known, however new targeted therapies are emerging that can reduce glucocorticoid exposure and achieve sustained clinical responses. Clinicians managing patients with such a rare and heterogeneous disease must therefore be aware of its varied phenotype and traditional and novel therapeutic strategies.
Identifiants
pubmed: 36960748
doi: 10.1080/1744666X.2023.2195627
doi:
Substances chimiques
Immunoglobulin G
0
Glucocorticoids
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM